Determination of burn depth with noncontact ultrasonography.

Early excision and grafting is the current treatment of choice for deep dermal and full-thickness burn wounds that will not heal spontaneously within 3 weeks. The time needed for the burn wound to heal is estimated with clinical assessment of the burn depth; this is often an inaccurate method. Therefore we have developed a new and unique noncontact ultrasonographic method to estimate burn depth. This study was designed to determine the practical utility and accuracy of noncontact ultrasonography for the assessment of burn depth. Seventy-eight burn sites and 42 normal skin sites (control sites) of 15 patients (age, 18-63 years) with burns of 2% to 35% total body surface area were evaluated. The burn sites were scanned with a prototype noncontact ultrasonographic system 1 and 3 days after the burn injuries. The probe was held 1 inch from the skin, and the time spent on each site was approximately 5 minutes. The ultrasonographic results were interpreted by an investigator who was blinded to the clinical findings. Clinical assessment of the burn wounds was made on the same days by 2 experienced physicians who were blinded to the results of the ultrasonography. The investigators were asked to categorize the burn wounds into those that would heal within 3 weeks and those that would not. With this method, we were able to visualize the epidermis, dermis, and dermal-fat interface in normal skin. The destruction of the dermal-fat interface was interpreted as a deep burn, which would not heal within 3 weeks. The overall accuracy of the noncontact ultrasonography in the prediction of which burn wounds would heal within 3 weeks was 96%. The results of this study show that noncontact ultrasonography will allow for the rapid evaluation of burn depth with high accuracy, without contacting the patient, and without causing pain or discomfort.

Uterine cervical extrarenal Wilms tumor managed without hysterectomy.

This report describes an unusual case of uterine cervical Wilms tumor treated successfully without hysterectomy or radiation therapy. The 12-year-old white girl developed a persistent vaginal discharge. Her pelvic examination revealed a large mass involving the entire upper vagina, obscuring the cervix. Biopsy of the mass was consistent with Wilms tumor with favorable histology. The tumor was not initially resected because the resection would involve hysterectomy and partial resection of the bladder wall. The patient was treated with preexcisional chemotherapy consisted of alternating vincristine, doxorubicin, cyclophosphamide and carboplatin/etoposide. Repeat magnetic resonance imaging after 5 weeks of chemotherapy demonstrated marked reduction of the tumor size. The tumor was easily removed by transsection of the stalk followed by cold-knife conization of the cervix. The patient received four more cycles of chemotherapy and remained in complete remission 12 months after completion of chemotherapy. This report suggests that in selected cases, chemotherapy can reduce tumor size sufficiently in patients with bulky cervical Wilms tumor to allow local resection and avoid hysterectomy.

Scintimammography: the new role of technetium-99m Sestamibi imaging for the diagnosis of breast carcinoma.

Technetium-99-Sestamibi scintimammography has emerged as a new procedure for the imaging of breast tumors. Currently, a large clinical experience has been developed and the results published. At the present time, the major drawback of this procedure appears to be its low sensitivity for the detection of breast carcinomas smaller than 1 cm in diameter. There are other biologic and technical issues that remain to be overcome to optimally image the breasts. Some of these include: development of a dedicated breast imager using nuclear medicine techniques, development of stereotactic needle localization of the abnormalities that demonstrate focal increase uptake in women with normal mammogram and breast physical examination, manufacturing of a breast compression device so that we can immobilize the breast in place for more adequate imaging, overcoming the issue of unilateral or bilateral diffuse breast uptake that is noted in 7-10 percent of the cases and finally, determination of optimal dose and imaging factors. This review includes our experience at Harbor-University of California, Los Angeles Medical Center with the use of this agent for breast imaging since 1992.

Breast Cancer Imaging: Can Tc-99m Sestamibi Scintimammography Fit In?

Mammography and physical examination are currently the most frequently used screening tests for breast cancer. Considering the 85% sensitivity associated with combined mammography and physical examination and a low positive predictive value of 20% to 30% for the diagnosis of breast carcinoma, there is a critical need for a more accurate noninvasive imaging test to improve the sensitivity and specificity of mammography. This study evaluates the role of Tc-99m sestamibi scintimammography as a complementary procedure to conventional mammography for the detection of breast carcinoma. A sample of 157 women (mean age 47.9 years +/- 10.2 years) with 164 lesions appropriate for histologic and cytologic analysis on the basis of suspicious findings on a mammogram and/or physical examination underwent scintimammography. Subsequently, excisional biopsy and/or fine-needle aspiration were performed. There were 52 primary cancers (8 different histopathologic types) and 112 benign breast lesions (6 different histopathologic types). The sensitivity of Tc-99m sestamibi scintimammography for detecting primary breast cancer was 92.3%, and its specificity was 87.5%. Percent-positive and -negative predictive values associated with Tc-99m sestamibi scintimammography in this cohort were 77.4% and 96.0%, respectively.

Scintimammography with Tc-99m sestamibi.

Mammography and physical breast examination are currently the most frequently and recognized screening tools for detection of breast carcinoma. These methods have been proved successful for early detection of breast cancer. Considering the 85% sensitivity associated with combined mammography and physical examination and a low positive predictive value of 20%-30% for diagnosis of breast carcinoma, there is a critical need for a more accurate, noninvasive imaging test to improve the sensitivity and specificity of mammography (7, 19, 20). Since early 1992, we have studied over 1200 women with clinically and/or mammographic abnormalities prior to breast biopsy and/or fine needle aspiration cytology of the breast. We have evaluated the role of Tc 99m Sestamibi as a complimentary procedure to conventional mammography in detection of breast carcinoma. The preliminary results of our studies have been published elsewhere (14, 17, 18). DuPont Merck Pharmaceutical Company in the USA on that basis, determined to conduct a multicenter clinical trial for the role of this radiopharmaceutical for the diagnosis of breast carcinoma in women with mammographically and/or clinically palpable abnormalities. This study was conducted at 42 institutions throughout the United States and Canada enrolling 673 women who where otherwise scheduled for breast biopsy and/or mastectomy. The preliminary results of this trial in both palpable and nonpalpable breast abnormalities are encouraging (24). Our most recent study on 157 women (mean age 47.9 years +/- 10.2) with 164 lesions with indications for histologic and cytologic analysis who underwent scintimammography with Tc 99m Sestamibi demonstrated the sensitivity of 92.3% and the specificity 87.5% (15). We have concluded that Scintimammography with Tc 99m Sestamibi can be used in conjunction with mammography to improve its specificity.